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Background: COPD is a prevalent disease that generates high use of resources. The objective of
this study was to quantify the economic consequences of non-adherence to GOLD guidelines
for the management of COPD patients.
Method: An economic model was generated to compare different scenarios of observed vs.
expected costs of COPD treatment. A pooled analysis of data derived from a systematic review
of studies describing treatment of COPD in Spain was combined with drug costs (using different
assumptions) to obtain the observed cost of COPD treatment. An expected cost was obtained
with the minimum and maximum treatment intensity derived from the GOLD recommenda-
tions.
Results: A total of 8 studies were identified, comprising 6339 patients. Average medication
cost of COPD patients was estimated as being between V1218 and V1314 per patient per year,
higher than the ideal expected average cost (between V1007 and V1021 per patient/year).
Thus, implementation of guidelines would result in a mean reduction of V198eV293 per
patient/year. Sensitivity analysis showed that about 13% of patients had higher treatmentmologia, Hospital Clı´nic, Villarroel 170, 08036 Barcelona, Spain. Tel./fax: þ34 93 227 55 49.
es (M. Miravitlles).
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Cost of treatment of COPD 715costs than the maximum expected cost. This proportion is much higher in moderately/severely
affected patients than in mildly affected patients (28.0% and 11.1%, respectively).
Conclusions: Treatment of COPD allows for the identification of areas of inefficiency. An
improvement in the adherence to the GOLD guidelines would imply potential savings of medi-
cation costs of about 20% of the observed costs.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Diseases of the respiratory tract represent the second
highest disease-cost category in the developed world only
exceeded by the costs associated with cardiovascular
diseases.1 Among respiratory diseases, chronic obstructive
pulmonary disease (COPD) is the most responsible for these
high costs. The prevalence of COPD in the general pop-
ulation of all ages is estimated as 1%, progressively
increasing to about 8e10% in those >40 years of age.2e5
Furthermore, COPD is the fourth highest cause for mortality
in Spain.6
The economic importance of COPD is highlighted by the
wealth of studies in several countries7e20 in which the costs
of the disease and its economic impact have been esti-
mated. In addition, there was an early Spanish study which
analyzed the economic repercussion of adherence to diag-
nosis and treatment recommendations.21
The Global Initiative for Chronic Obstructive Lung
Disease (GOLD) guidelines are the most widely accepted
recommendations for treatment.4 The use of treatments
not contained in the recommendations, including those
beyond clinical indications, provides an opportunity to
assess areas of inefficiency and evaluate the eventual
impact of a better implementation of the guidelines. The
objective of the present study was to assess the costs
associated with deviations from the GOLD guidelines of
therapeutic recommendations in Spain.Methods
The present study attempted to analyze the differences
between direct costs of the COPD treatment in Spain
(observed cost) and the estimated costs proceeding from
the ideal management defined by the GOLD guidelines4
(expected costs). Our analysis was based on the information
obtained from a systematic review of published studies of
the pharmacological treatment for patients with COPD
(Fig. 1). Studies had to fulfill the following criteria to be
included in the review: a) published after 1990 and before
the date of the analysis (January 2008); b) multicenter
studies representing the whole country; c) a minimum
sample size of 200 COPD patients; and d) spirometric
diagnosis of COPD and FEV1 values available. The sources of
the articles were MEDLINE, EMBASE and SCOPUS with the
keywords ‘‘COPD’’, ‘‘treatment’’ and ‘‘Spain’’, supple-
mented by hand searching of leading respiratory journals
and references of the retrieved articles without any
language restriction.
Since it was not possible to analyze each study compared
with the guidelines in place at the time of data collection,
we chose the GOLD recommendations published in 2001 asthe gold standard for the calculation of the costs of ideal
treatment of COPD.4 With this approach we estimated the
average cost of deviations from the guidelines, although we
could not attribute these costs to non-adherence, because
some data were collected before these guidelines were
published.
Calculation of the observed (clinical practice) costs
of COPD
Data derived from the systematic review of studies fulfilling
the predefined criteria. It was taken into account that
many of the patients who appeared in the studies within
the ‘‘long-acting B2 inhalers’’ (LABA) and ‘‘inhaled corti-
costeroids’’ (IC) groups had actually been prescribed
a combined inhaler. To avoid this bias, we introduced
a correction based on the data of the International
Marketing Services (IMS) from 2004 and data from a recent
Spanish study published in 2008.22 To estimate the cost due
to the use of Tiotropium bromide, we assumed that its use
was equivalent to that recorded in the most recent study22
since the remaining studies had been conducted before the
launch of this bronchodilator.
The annual cost of pharmacological treatment was
estimated based on the public sale price in Eurox (PSP) in
place in the year 2005,24 together with the daily dose
options (minimum and maximum) of the different drugs
(see Table 1) assuming 100% compliance and 12 months of
complete treatment per year.
To calculate the observed costs, we defined different
scenarios according to the possible options of daily costs of
the different treatment groups, with the objective of
obtaining a range of plausible outcomes. We estimated
a minimum and a maximum cost for each drug based on the
PSP and the recommended dosage.
Scenario 1 or extreme costs
To calculate the minimum range of the costs we assumed
that the patients were treated with the lowest cost of
each therapeutic group and at the minimum recom-
mended dose. The corresponding maximum range was
obtained assuming that the patients were treated with
the most expensive drug at the maximum recommended
dose.
Scenario 2 or average cost
To calculate the minimum range we assumed that the
patients were treated at the mean cost of all the specialties
at the minimum recommended dose in each case. The
maximum range was obtained assuming that the patients
were treated at the mean maximum cost of each thera-
peutic group.
Figure 1 Study scheme.
716 M. Miravitlles et al.Scenario 3 or extreme costs in primary care
This was equivalent to scenario #1 but the information of
the studies was used only if data about treatment were
collected in Primary Care Centers (PCC).
Calculation of the expected costs according to
GOLD 2001
Two different scenarios based on the maximum and
minimum ranges of costs were developed. To calculate the
minimum range of cost we assumed that, in cases in which
the GOLD guidelines allow different options, the mean
minimum cost was calculated for the cheapest options from
among them. The maximum range was obtained assuming
a combination of all the possible drugs and was calculated
as the mean maximum cost of all of them.Table 1 Unit costs of the drug treatment.
Principal active ingredient
Short-acting b2-agonists Salbutamol
Terbutaline
Long-acting b2-agonists Formoterol fumarate
Formoterol fumarate dihydr
Salmeterol
Inhaled corticosteroids Beclomethasone
Budesonide
Fluticasone
LABAþ inhaled corticosteroids Budesonide/formoterol
Fluticasone/salmeterol
Anticolinergics Ipratropium bromide
Tiotropium
Oral corticosteroids Dezacort
Prednisone
Oral b2-agonists Salbutamol
TheophyllineThe mean number of daily inhalations of on-demand sal-
butamol was estimated from the data of Calverley et al.25 To
estimate the proportion of patients who are candidates for
theophyllines in real life, we performed a conservative
estimation by assuming that the proportions of patients who
receive theophyllines coincided with those of population
studies; 39.4% (see Table 3). To estimate the appropriate use
of IC we used data from the ISOLDE study.26 According to this
study, 37% of patients with FEV1< 50% predicted suffered
more than 1 exacerbation/year, similar to the IMPAC study
(31.8%).27 Hence, we assumed that a mean of 34.4% of the
patients with COPD and FEV1< 50% had more than 1 episode
per year. Tiotropium was not specifically addressed in the
GOLD 2001 guidelines. For the calculation of expected costs,
it was included in the group of long-acting bronchodilators
together with salmeterol and formoterol.Mean V/d (minimum) Mean V/d (maximum)
0.000 0.236
1.163 2.326
ate
0.651 1.203
2.527 2.527
0.834 1.103
0.681 3.455
0.162 0.431
0.201 0.347
Cost of treatment of COPD 717Avoidable costs were calculated as the difference
between the expected costs and the observed costs. This
calculation was made for each of the scenarios and classi-
fied into two groups according to severity of COPD.
Sensitivity analysis
A probabilistic sensitivity analysis was performed to
incorporate the uncertainty of the parameters of the
model into the results of the study. For this aim, results
were generated for a hypothetical sample of 1000 indi-
viduals using a non-parametric Monte-Carlo simulation
based on the different probabilities of receiving a specific
treatment based on the observational studies analyzed and
on the range of costs (maximum and minimum) of the drug
used (Table 1). The results of these analyses provide
additional information on the distribution of patients
having an annual pharmacological cost above or below the
ideal range of values obtained when following the GOLD
recommendations.
Results
A total of 64 articles published between 1990 and 2007
were identified. Six were reviews, 5 were secondary
publications from the same database, 5 reported the
economic impact of one drug, 4 were related to oxygen
therapy, non-invasive mechanical ventilation or rehabili-
tation, 18 referred to treatment of hospitalised COPD, 11 to
treatment of exacerbated COPD, 4 to other comorbid
illnesses such as pneumonia and ischemic heart disease,
and 1 included data from a single center.33 Another study
did not include the use of drugs according to lung function34
leaving 8 studies for final analysis: seven observational
studies16,19,23,28e31 and one nationwide clinical trial32
(Table 2). The number of patients in each trial ranged from
253 to 1164 with a total of 6639 patients included, with
a mean age ranging from 66.1 to 69.1 years and a mean
FEV1 (% predicted) from 33 to 57% (Table 2). The data on
the use of drugs in overall numbers and according to
pulmonary function are shown in Table 3. After closing the
database and analysing the data, another study was pub-
lished22 and the data from this study are commented in the
Discussion.
The results of cost per patient per year of the three
scenarios defined for clinical practice (or observed cost)Table 2 Characteristics of the various studies included in the p
Author (Ref.) Year of study Setting Pa
Miravitlles28 1994e1995 PC 10
Miravitlles19 1996e1997 PC 7
Miravitlles27 1999 PN 4
De Miguel30 2000 PC and PN 5
Alvarez-Mon32 2000 PN 2
Miravitlles31 2002 PN 10
Llor16 2001e2002 PC 11
Miravitlles23 2003 PC 11
SDZ standard deviation; PCZ primary care; and PNZ pneumology.and the ideal recommended (or expected costs) as well as
the avoidable costs are summarised in Table 4. The positive
values in the avoidable costs represent an excessive and
avoidable cost in clinical practice related to the cost
derived from guidelines.
The drug costs of COPD per patient per year according to
clinical practice were very similar in the three scenarios
considered in our study. Scenario 1 shows that the mean
cost per patient per year was V1314; for scenario 2 it was
V1218 and for studies that only consider primary care it was
V1221.
With respect to the expected costs, the mean cost per
patient per year was V1021. The mean savings per patient
per year that could be achieved if the recommended
guidelines were adopted varied between V198 (scenario 2)
and V293 (scenario 1). The usual clinical practice for the
treatment of COPD generated a greater cost than that
expected of between V234 and V520 per patient per year
for the patients treated with cheapest drugs. At the other
extreme, when the most costly drugs of each therapeutic
group were used, the cost per patient per year in standard
clinical practice in one of the scenarios analyzed was lower
(V125; Table 4) than the expected costs (scenario 2).
When the same analyses were performed based on the
severity of COPD, the results showed considerable cost
excess (up to V540/patient/year) in the low-cost drug band
in patients with FEV1Z 50e80%.
Sensitivity analysis
The results of the simulation showed that in 90% of the
patients the costs were above the mean cost calculated
according to the GOLD guidelines, and up to 13% above the
maximum cost. This opportunity for reducing the drug costs
was especially clear in patients with the more severe
disease (FEV< 50%) in whom 28% had a higher cost than the
maximum expected cost (Fig. 2). In the PC model, the
proportion of patients who could reduce their drug costs
was slightly lower (79.6%), and was higher in patients with
more severe disease (Fig. 3).
Discussion
The results of our study indicate that costs resulting from
deviation from the guidelines of pharmacological treatment
of COPD are excessive. The savings that could be obtainedresent analysis.
tients; N Age: mean (SD) FEV1 (%); mean (SD)
01 68 (9) 47 (13)
66 66.3 (10.5) 56.5 (16.3)
41 66.1 (8.2) 33 (8)
68 67.9 (8.9) 48.6 in PC
43.5 in PN
53 67.9 (7.9) 48.8 (10.3)
28 66.8 (9) 41.8 (13.2)
64 68.2 (10.3) 52.3 (13.9)
18 69.1 (10.6) 57 (21.5)
Table 3 Treatment received by the COPD patients in different Spanish studies.
Ref. 19 Ref. 28 Ref. 30 Ref. 27 Ref. 31 Ref. 23 Ref. 16 Ref. 32 Overalla
FEV1,
>50%
FEV1,
<50%
FEV1,
>50%
FEV1,
<50%
FEV1,
>50%
FEV1,
<50%
FEV1,
<50%
FEV1,
>50%
FEV1,
<50%
FEV1,
>50%
FEV1,
<50%
FEV1,
>50%
FEV1,
<50%
FEV1,
>50%
FEV1,
<50%
FEV1,
>50%
FEV1,
<50%
Study sample; N 512 254 355 646 148 420 441 357 671 702 416 679 485 115 138 2868 3471
Medications; as percentage of the total N in the study
Theophyllines 34.4 51.6 41.7 59.6 28.5 45.2 40.8 14.3 32.5 10.7 20.8 19.7 27.2 20.9 31.9 22.8 39.4
Oral b2 4.5 3.1 0.0 0.0 0.0 0.2 0.0 3.4 2.2 1.6 1.5 5.8 8.1 0.0 0.0 3.0 2.2
Mucolytics 25.0 30.3 22.8 26.3 9.0 14.4 6.6 17.9 25.6 21.5 24.6 40.0 67.9 0.0 0.0 24.5 29.6
Oral corticosteroids 4.1 15.0 0.0 0.0 3.5 5.8 6.8 1.7 4.6 6.6 9.0 23.2 23.4 0.0 0.0 8.0 7.8
Short-acting
b2 inhalers
55.5 71.3 62.5 75.2 57.6 68.8 64.9 58.5 71.5 51.6 60.9 59.4 81.8 45.2 52.2 56.4 71.1
Long-acting
b2 inhalers
43.4 53.5 0.0 0.0 38.2 48.6 59.0 73.7 87.0 55.6 66.7 54.5 88.1 54.8 71.7 16.8 19.4
Ipratropium bromide 32.0 45.3 17.7 26.3 68.1 80.5 87.3 84.0 91.5 31.3 36.1 46.7 74.4 60.0 65.2 43.0 60.6
Inhaled
corticosteroids
41.8 62.2 42.5 54.0 52.1 64.9 69.4 61.1 82.9 51.3 65.2 56.3 87.4 64.3 68.8 18.2 24.0
Oxygenoterapy 5.1 15.7 0.0 0.0 0.0 0.0 0.0 5.0 23.8 0.0 0.0 10.8 7.6 2.6 7.2 4.1 8.2
Tiotropium 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 29.4 38.8 0.0 0.0 0.0 0.0 29.4 38.8
Combined B2/inhaled
corticosteroids
63.9 83.0
a Modified according to the data from IMS 2004 taking into account the combination of long-acting bronchodilatorsþ inhaled corticosteroids.
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Table 4 Cost (in euros) per patient per year of the treatments received by patients with COPD.
Real cost (observed) Ideal cost (expected) Costs avoided (observedeexpected)
Mean Mı´n. Max. Mean Mı´n. Max. Mean Mı´n. Max.
Cost per patient (Overall)
Scenario 1 1314 781 1847 1021 478 1563 293 303 284
Scenario 2 1218 998 1438 198 520 125
Scenario 3 1221 712 1729 200 234 166
Cost per patient (FEV 50e80%)
Scenario 1 1149 675 1623 925 325 1524 224 349 99
Scenario 2 1061 866 1256 136 540 268
Scenario 3 1107 639 1575 182 314 51
Cost per patient (FEV< 50%)
Scenario 1 1470 882 2058 1111 622 1600 359 259 458
Scenario 2 1367 1124 1610 256 501 11
Scenario 3 1363 804 1922 252 181 323
Cost of treatment of COPD 719from adherence to the treatment guidelines could reach up
to V540 per patient per year in patients with moderate
COPD. The use of the treatments not included in the
guidelines may have a direct impact on the quality of life of
these patients and on the costs.
Several scenarios of treatment costs were analyzed in
order to evaluate them from a point of view that most
closely relates to the reality of clinical practice. In all the
scenarios considered, the mean cost per patient per year
would have been less if the recommended guidelines had
been followed. The only exception was in the maximum
costs according to scenario 2 (or average costs) due,
essentially, to the subgroup of patients with FEV1 between
50% and 80% in whom the costs observed were lower than
the average maximum cost according to the GOLD treat-
ment guidelines. This implies that in the patients with more
symptoms, that is, in those in whom the treatment needs to
be intensified, the maximum treatment recommended is,
probably, not reached. On the other hand, in the group of
patients with FEV1 between 50% and 80% we also observed
the greatest excess in costs in the standard clinical practice
compared to guidelines. This means that very few patients
are treated at the minimum treatment option as describedFigure 2 Deviations from the GOLD guidelines using a simu-
lation of 1000 individuals. Proportion of patients simulated
with a cost lower than the expected mean (white), above the
expected mean (grey) and above the maximum expected cost
(black).by the guidelines and this is the cause of a considerable
increase in cost.
In many studies the treatment of patients with COPD
differ from the recommendations of guidelines and, as
such, further increase the economic burden of the dis-
ease.28,30,33,35e37 The costs of drug treatment of COPD
observed in the present study are comparable to those
obtained in previous studies. For example, in a series of
ambulatory patients, the mean annual treatment cost per
patient was V785 in 2004.18 In a previous study, our group
had calculated the yearly drug cost as V821.19 Other
European studies have had similar findings. In Sweden, the
costs associated with drug treatment varied between 2230
SEK in 1999 for mild patients and 13 440 SEK for severe
patients.8 A value of V646 was obtained in France in 2004.9
Two recent studies in Italy reported similar costs; one study
with V836 representing 37% of the direct costs of COPD in
a cohort of hospitalised patients in 2005,10 and the other
study calculated V700 as the mean cost per patient/year in
2007.11 Similar data have been reported for the USA. In one
series of hospitalised patients, Hillemann et al.12 obtained
a cost that varied between $512 for the year 2000 for
patients with mild disease, and $1400 for patients withFigure 3 Deviations from the GOLD guidelines using a simu-
lation of 1000 individuals receiving attention in Primary Care.
Proportion of patients simulated with a cost below the
expected mean cost (white), above the expected mean (grey)
and above the expected maximum cost (black).
720 M. Miravitlles et al.severe disease. In a large cohort of ambulatory patients the
cost was calculated as $509 for the year 2001.13 The simi-
larity of these results with the data reported in our study
suggests that our current results can be extrapolated, in
large part, to other countries, while taking into account the
most-used treatment patterns in each country.
The present study has three main limitations. Firstly, the
estimation of an ‘‘ideal’’ cost of the treatment of patients
with COPD based on the GOLD guidelines is not easy and is
subjected to different interpretations. Therefore, it is not
always possible to estimate with precision in which
percentage of patients in each severity stage would require
each of the recommended treatments. To overcome this
limitation we defined the different scenarios and calcu-
lated the extreme cases (maximum and minimum costs),
which enabled a better interpretation of the results.
Secondly, for the calculation of annual costs, both
observed and expected, we assumed that adherence was
100% and calculated the cost for 12 months per year. It is
well documented that adherence to medication for respi-
ratory illness is low.38 However, this assumption enabled
a better estimation of the total impact of deviations of
standard clinical practice from that of guidelines in an ideal
situation.
The third limitation is that we cannot discard the
possibility that some deviations of treatment from those
recommended by guidelines are, indeed, justified. The
treatment guidelines are based on evidence from
controlled clinical trials but the patients included in the
trials are not always representative of all the patients with
COPD in the community.39 Hence, it is possible that, on
occasions, deviations from the recommended treatment
guidelines can be justified in certain specific clinical situ-
ations. Another consideration is that the costs of COPD also
involve other aspects such as medical visits, hospital-
isations, etc; however, they are beyond the scope of the
current analysis.
After concluding the current study, an update of the
GOLD guidelines was published.40 The changes contained in
this new version of the guidelines were minimal and would
not significantly change the calculations of expected costs
and therefore, do not significantly affect the reliability of
our results. Similarly, the most recent study providing
estimates of the use of respiratory drugs for COPD in
Spain,22 published after the database was closed, did not
show significant discrepancies with the drug use reported in
our analysis. Furthermore, the robustness of the analysis
was also tested using only the data derived from this most
recent study to calculate the observed costs of COPD,22
with no relevant changes in the final results (data not
shown).’’
Another study could not be included because the use of
drugs according to lung function was restricted to inhaled
corticosteroids and showed that 73.4% of patients with
moderate disease and 69% of patients with mild disease
were using them.34
In conclusion, our results show that there is an excessive
cost derived from the pharmacological treatment of COPD
in the community in Spain. Adherence to guidelines
would imply mean savings of V198 per patient per year or
of up to V540 in moderate COPD. Since it is estimated
that approximately 300 000 patients are receivingpharmacological treatment for COPD in Spain,5 non-
adherence to guidelines may produce an excess cost of V59
million per year.Acknowledgment
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